Efficacy of latanoprost and timolol maleate in black and white patients

Advances in Therapy

Volumn 21, Issue 4, 2004, Pages 203-213

  Kitnarong, Naris ^a   Zhao, Yuling ^a   Netland, Peter A ^a   Kent, Alexander R ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Latanoprost; Ocular hypertension; Open angle glaucoma; Timolol

Indexed keywords

LATANOPROST; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EYE BURNING; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

EID: 8744271181     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850153     Document Type: Article

References (29)

1. Racette L, Wilson MR, Zangwill LM, et al. Primary open-angle glaucoma in blacks: a review. Sum Ophthalmol. 2003;48:295-313.
2. Wilensky JT, Gandhi N, Pan T. Racial influences in open-angle glaucoma. Ann Ophthalmol. 1978;10:1398-402.
3. Wilson R, Richardson TM, Hertzmark E, Grant WM. Race as a risk factor for progressive glaucomatous damage. Ann Ophthalmol. 1985;17:653-659.
4. Martin MJ, Sommer A, Gold EB, Diamond EL. Race and primary open-angle glaucoma. Am J Ophthalmol. 1985;99:383-387.
5. Broadway D, Grierson I, Hitchings R. Racial differences in the results of glaucoma filtration surgery: are racial differences in the conjunctival cell profile important? Br J Ophthalmol. 1994;78:466-475.
6. Katz IM, Berger ET. Effects of iris pigmentation on response of ocular pressure to timolol. Surv Ophthalmol. 1979;23:395-398.
7. Salminen L, Imre G, Huupponen R. The effect of ocular pigmentation on intraocular pressure response to timolol. Acta Ophthalmol Suppl. 1985;173:15-18.
8. Netland PA, Robertson SM, Sullivan EK, et al. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension. Adv Ther. 2003;20:149-163.
9. Shimmyo M, Ross AJ, Moy A, Mostafavi R. Intraocular pressure, Goldmann applanation tension, corneal thickness, and corneal curvature in whites, Asians, Hispanics, and African Americans. Am J Ophthalmol. 2003;136:603-613.
10. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
11. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351-1358.
12. Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol. 1996;7:11-17.
13. Stjernschantz J, Selen G, Astin M, et al. Effect of latanoprost on regional blood flow and capillary permeability in the monkey eye. Arch Ophthalmol. 1999;117:1363-1367.
14. Resul B, Stjernschantz J, No K, et al. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J Med Chem. 1993;36:243-248.
15. Stjernschantz J. Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:63-68.
16. Camras CB, Wax MB, Ritch R, et al. Latanoprost treatment for glaucoma: effects of treating for 1 year and of switching from timolol. United States Latanoprost Study Group. Am J Ophthalmol. 1998;126:390-399.
17. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology. 1996;103:1916-1924.
18. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group. Ophthalmology. 1998;105:82-87.
19. Alm A, Widengård I. Latanoprost: experience of 2-year treatment in Scandanavia. Acta Ophthalmol Scand. 2000;78:71-76.
20. Hedmana K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47(suppl 1):S65-76.
21. Alm A, Schoenfelder J, McDermott J. A 5-year multicenter, open-label safety study of adjunctive latanoprost for glaucoma. Arch Ophthalmol. 2004;122:957-965.
22. Netland PA, Schwartz B, Feke GT, et al. Diversity of response of optic nerve head circulation to timolol maleate in gel-forming solution. J Glaucoma. 1999;8:164-171.
23. Seddon JM, Sahagian CR, Glynn RJ, Sperduto RD, Gragoudas ES. Evaluation of an iris color classification system. Invest Ophthalmol Vis Sci. 1990;31:1592-1598.
24. Hedman K, Larsson L-I. The effect of latanoprost compared with timolol in black, Asian, white, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(suppl 1):S77-S89.
25. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
26. Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688-703.
27. Noecker RJ, Earl ML, Mundorf T, Peace J, Williams RD. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther. 2003;20:121-128.
28. Camras CB, Minckler D. Does that drug work? Pitfalls in studies on the efficacy and safety of glaucoma medications. Am J Ophthalmol. 2000;129:87-89.
29. Eisenberg DL, Toris CB, Camras CB. Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol. 2002;47(suppl):S105-S115.